World Heart
This article was originally published in The Gray Sheet
Executive Summary
Files for a secondary offering of 2 mil. common shares by the company and a separate offering of 300,000 shares by a selling shareholder. The first human implant of the Ottawa, Ontario firm's HeartSaver ventricular assist device is expected by year-end, and proceeds from the offering are tabbed for continuing R&D, product development and commercialization. World Heart and the selling shareholder will grant overallotment options of 300,000 and 45,000 shares, respectively, to offering managers Merrill Lynch Canada, ScotiaMcLeod and CIBC Wood Gundy Securities